In the good books
ALS (ALQ) Upgraded to Buy from Sell by Citi B/H/S: 3/3/1
ALS Ltd's financial performance proved a mild beat on Citi's expectations. Incorporating revised commodities prices forecasts plus recent acquisitions in Life Sciences have triggered higher forecasts. As a result, the price target rises to $6.90 from $5.60.
Combine the above with share price weakness and Citi analysts have made the decision to implement a double-whammy upgrade; to Buy from Sell. The analysts like the company's industry and geographic diversity and are now forecasting double digit growth for the years ahead.